The effect of hypoglycemic therapy on the course of the wound process in patients with type 2 diabetes and/or obesity.



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

This review analyzes publications on the effect of hypoglycemic drugs on the wound healing process. Diabetes mellitus andobesity have a negative effect on wound repair processes, slowing down and disrupting their progression, which leads to the appearance of chronic non-healing wounds. The current understanding of the use of antidiabetic drugs is currently changingsignificantly. In addition to the main hypoglycemic effect, it is of interest to study the pleiotropic effects of both metformin, which has been used in clinical practice for more than 60 years, and more modern drugs from the SGLT-2 inhibitors, DPP-4 inhibitors groups, sulfonylureas, meglitinides, GLP-1 receptor agonists and the double GLP-1/GIP agonist tirzepatide. The anti-inflammatoryand reparative effects of these drugs are being investigated, the implementation of which in practice may open up new prospects inthe treatment of wounds. There have been accumulated studies in which the use of drugs of these groups demonstrated a positiveeffect on regenerative processes both in vitro and reduced the time and improved the quality of wound healing in vivo. Promisingareas of further research are determined by the authors to evaluate the effectiveness of using incretin-type drugs and topical forms of hypoglycemic drugs as wound healing agents, including for acute wounds not associated with metabolic disorders, as well as the safety of their use in humans, including with their neutral metabolic status.

Full Text

Restricted Access

About the authors

Mikhail O. Gurba

Military Medical Academy n.a. S.M. Kirov

Author for correspondence.
Email: mikhail.gurba@yandex.ru
ORCID iD: 0000-0002-2257-5556
SPIN-code: 9736-2989

Адъюнкт (отдела научной работы и подготовки научно-педагогических кадров) 

Russian Federation, 194044, Russia, Saint Petersburg, Akademika Lebedeva 6G

Vladimir V. Salukhov

Military Medical Academy named after S.M. Kirov

Email: vv@salukhov.ru
ORCID iD: 0000-0003-1851-0941
SPIN-code: 4531-6011
Scopus Author ID: 55804184100

Chief of the 1st Department of Advanced Medical Studies n.a. acad. N. S. Molchanov, MD, PhD, professor

Russian Federation, 194044, Russia, Saint Petersburg, Academica Lebedeva street 6G.

References

  1. Karas RA, Alexeree S, Elsayed H, Attia YA. Assessment of wound healing activity in diabetic mice treated with a novel therapeutic combination of selenium nanoparticles and platelets rich plasma. Sci Rep. 2024;14(1):5346. doi: 10.1038/s41598-024-54064-2
  2. Shojaeian A. Harnessing the Power of Non-diabetic Benefits of Metformin Derived from Galega officinalis: Focus on Wound Healing. J Wound Manag Res. 2024;20(3):212-218. doi: 10.22467/jwmr.2024.02957
  3. Reinke JM, Sorg H. Wound Repair and Regeneration. Eur Surg Res. 2012;49(1):35-43. doi: 10.1159/000339613
  4. Wang PH, Huang BS, Horng HC, et al. Wound healing. Journal of the Chinese Medical Association. 2018;81(2):94-101. doi: 10.1016/j.jcma.2017.11.002
  5. Fernández-Guarino M, Hernández-Bule ML, Bacci S. Cellular and Molecular Processes in Wound Healing. Biomedicines. 2023;11(9):2526. doi: 10.3390/biomedicines11092526
  6. Jeschke MG, van Baar ME, Choudhry MA, et al. Burn injury. Nat Rev Dis Primers. 2020;6(1):11. doi: 10.1038/s41572-020-0145-5
  7. Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006;17(1):4-12.
  8. Brem H, Tomic-Canic M. Cellular and molecular basis of wound healing in diabetes. J Clin Invest. 2007;117(5):1219-1222. doi: 10.1172/JCI32169
  9. Brass LF, Bensusan HB. On the role of the collagen carbohydrate residues in the platelet. Collagen interaction. Biochim Biophys Acta. 1976;444(1):43-52. doi: 10.1016/0304-4165(76)90222-1
  10. Salukhov VV, Asadova LA, Varavin NI. Disordered carbohydrate metabolism and its impact on hemostasis: from hypercoagulation to cardiovascular complications. Russian Medical Inquiry. 2025;9(10):735-742 (in Russ.). doi: 10.32364/2587-6821-2025-9-10-6
  11. Greaves J, Pula G. Hyperactivity and Pro-inflammatory Functions of Platelets in Diabetes. Front Biosci (Landmark Ed). 2025;30(1):26190. doi: 10.31083/FBL26190
  12. Alsharidah AS. Diabetes mellitus and diabetic nephropathy: a review of the literature on hemostatic changes in coagulation and thrombosis. Blood Res. 2022;57(2):101-105. doi: 10.5045/br.2022.2021204
  13. Kaur R, Kaur M, Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies. Cardiovasc Diabetol. 2018;17(1):121. doi: 10.1186/s12933-018-0763-3
  14. Andrade TAM, Masson-Meyers DS, Caetano GF, et al. Skin changes in streptozotocin-induced diabetic rats. Biochem Biophys Res Commun. 2017;490(4):1154-1161. doi: 10.1016/j.bbrc.2017.06.166
  15. Muniyappa R, Sowers JR. Role of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord. 2013;14(1):5-12. doi: 10.1007/s11154-012-9229-1
  16. O’Hara A, Pozin J, Darki A, et al. Glycemic Control and Plasma Levels of Pro-Inflammatory and Pro-Thrombotic Biomarkers in Diabetic Patients Presenting with Acute Pulmonary Embolism. Clin Appl Thromb Hemost. 2023;29:10760296231165058. doi: 10.1177/10760296231165058
  17. Bybee JD, Rogers DE. The phagocytic activity of polymorphonuclear leukocytes obtained from patients with diabetes mellitus. J Lab Clin Med. 1964;64:1-13
  18. Bagdade JD, Root RK, Bulger RJ. Impaired leukocyte function in patients with poorly controlled diabetes. Diabetes. 1974;23(1):9-15. doi: 10.2337/diab.23.1.9
  19. Jafar N, Edriss H, Nugent K. The Effect of Short-Term Hyperglycemia on the Innate Immune System. Am J Med Sci. 2016;351(2):201-211. doi: 10.1016/j.amjms.2015.11.011
  20. Mowat A, Baum J. Chemotaxis of polymorphonuclear leukocytes from patients with diabetes mellitus. N Engl J Med. 1971;284(12):621-627. doi: 10.1056/NEJM197103252841201
  21. Dong H, Sun Y, Nie L, et al. Metabolic memory: mechanisms and diseases. Sig Transduct Target Ther. 2024;9(1):38. doi: 10.1038/s41392-024-01755-x
  22. Hofmann MA, Drury S, Qu W, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell. 1999;97(7):889-901. doi: 10.1016/s0092-8674(00)80801-6
  23. Senn JJ, Klover PJ, Nowak IA, Mooney RA. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes. 2002;51(12):3391-3399. doi: 10.2337/diabetes.51.12.3391
  24. Wetzler C, Kämpfer H, Stallmeyer B, et al. Large and sustained induction of chemokines during impaired wound healing in the genetically diabetic mouse: prolonged persistence of neutrophils and macrophages during the late phase of repair. J Invest Dermatol. 2000;115(2):245-253. doi: 10.1046/j.1523-1747.2000.00029.x
  25. Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. Nature. 2017;542(7640):177-185. doi: 10.1038/nature21363
  26. Aronson D, Rayfield EJ. How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc Diabetol. 2002;1:1. doi: 10.1186/1475-2840-1-1
  27. Zhao M, Wang S, Zuo A, et al. HIF-1α/JMJD1A signaling regulates inflammation and oxidative stress following hyperglycemia and hypoxia-induced vascular cell injury. Cell Mol Biol Lett. 2021;26:40. doi: 10.1186/s11658-021-00283-8
  28. Lien YH, Stern R, Fu JC, Siegel RC. Inhibition of collagen fibril formation in vitro and subsequent cross-linking by glucose. Science. 1984;225(4669):1489-1491. doi: 10.1126/science.6147899
  29. O’Sullivan JB, Hanson R, Chan F, Bouchier-Hayes DJ. Tight glycaemic control is a key factor in wound healing enhancement strategies in an experimental diabetes mellitus model. Ir J Med Sci. 2011;180(1):229-236. doi: 10.1007/s11845-010-0630-z
  30. Spanheimer RG, Umpierrez GE, Stumpf V. Decreased Collagen Production in Diabetic Rats. Diabetes. 1988;37(4):371-376. doi: 10.2337/diab.37.4.371
  31. Seifter E, Rettura G, Padawer J, et al. Impaired wound healing in streptozotocin diabetes. Prevention by supplemental vitamin A. Ann Surg. 1981;194(1):42-50. doi: 10.1097/00000658-198107000-00008
  32. Tellechea A, Kafanas A, Leal EC, et al. Increased Skin Inflammation and Blood Vessel Density in Human and Experimental Diabetes. Int J Low Extrem Wounds. 2013;12(1):4-11. doi: 10.1177/1534734612474303
  33. Burgess JL, Wyant WA, Abdo Abujamra B, et al. Diabetic Wound-Healing Science. Medicina (Kaunas). 2021;57(10):1072. doi: 10.3390/medicina57101072
  34. Spravchikov N, Sizyakov G, Gartsbein M, et al. Glucose Effects on Skin Keratinocytes: implications for diabetes skin complications. Diabetes. 2001;50(7):1627-1635. doi: 10.2337/diabetes.50.7.1627
  35. Lerman OZ, Galiano RD, Armour M, et al. Cellular Dysfunction in the Diabetic Fibroblast. Am J Pathol. 2003;162(1):303-312. doi: 10.1016/S0002-9440(10)63821-7
  36. Bermudez DM, Herdrich BJ, Xu J, et al. Impaired Biomechanical Properties of Diabetic Skin. Am J Pathol. 2011;178(5):2215-2223. doi: 10.1016/j.ajpath.2011.01.015
  37. Bartling B, Desole M, Rohrbach S, et al. Age‐associated changes of extracellular matrix collagen impair lung cancer cell migration. The FASEB Journal. 2009;23(5):1510-1520. doi: 10.1096/fj.08-122648
  38. Galstyan GR., Dedov II. Principles of care in diabetic foot patients in Russia. Diabetes mellitus. 2009;12(1):4-7 (in Russ.). doi: 10.14341/2072-0351-5411
  39. Omotosho IA, Shamsuddin N, Zaman Huri H, et al. From Control to Cure: Insights into the Synergy of Glycemic and Antibiotic Management in Modulating the Severity and Outcomes of Diabetic Foot Ulcers. IJMS. 2025;26(14):6909. doi: 10.3390/ijms26146909
  40. Wang F, Zhang W, Li H, et al. How Effective are Nano-Based Dressings in Diabetic Wound Healing? A Comprehensive Review of Literature. International Journal of Nanomedicine. 2022;17:2097-2119. doi: 10.2147/IJN.S361282
  41. Komelyagina EY, Antsiferov MB. Clinical features and poutcomes of recalcitrant ulcers in diabetic foot patients: a retrospective cohort study. Endocrinology: News, Opinions, Training. 2020;9(3):21-25. doi: 10.33029/2304-9529-2020-9-3-21-25
  42. Salukhov VV, Zelenina TA, Akhmedova KS, et al. The short- and long-term results of therapy of surgical diabetic foot patients. Medical Council. 2024;(16):154-161 (In Russ.). doi: 10.21518/ms2024-395
  43. Zemlyanoy AB , Zelenina TA, Rybakov AO, Salukhov VV. A new IORDAN classification for prognosis of the healing of postoperative diabetic foot wounds and subsequent routing of the patients. Medical Bulletin of the Ministry of Internal Affairs. 2025;2025(2):12-19 (In Russ.). doi: 10.52341/20738080_2025_135_2_12
  44. Salukhov VV, Galstyan GR, Khalimov YS, et al. Practical application of semaglutide: From evidence-based research to expert decisions. Medical Council. 2025;19(6):14-29 (in Russ). doi: 10.21518/ms2025-185
  45. Dedov II, Shestakova MV, Sukhareva OU, et al. Standards of specialized diabetes care. 12th Edition. 2025. doi: 10.14341/DM20255S
  46. Romantsova TI, Sych YP. Immunometabolism and metainflammation in obesity. Obesity and metabolism. 2019;16(4):3-17 (in Russ.). doi: 10.14341/omet12218
  47. Lin H, Ao H, Guo G, Liu M. The Role and Mechanism of Metformin in Inflammatory Diseases. J Inflamm Res. 2023;16:5545-5564. doi: 10.2147/JIR.S436147
  48. Vianello E, Beltrami AP, Aleksova A, et al. The Advanced Glycation End-Products (AGE)–Receptor for AGE System (RAGE): An Inflammatory Pathway Linking Obesity and Cardiovascular Diseases. IJMS. 2025;26(8):3707. doi: 10.3390/ijms26083707
  49. de Jager J, Kooy A, Schalkwijk C, et al. Long-term effects of metformin on endothelial function in type 2 diabetes: a randomized controlled trial. J Intern Med. 2014;275(1):59-70. doi: 10.1111/joim.12128
  50. Witkowski M, Friebel J, Tabaraie T, et al. Metformin Is Associated with Reduced Tissue Factor Procoagulant Activity in Patients with Poorly Controlled Diabetes. Cardiovasc Drugs Ther. 2021;35(4):809-813. doi: 10.1007/s10557-020-07040-7
  51. Shi L, Jiang Z, Li J, et al. Metformin Improves Burn Wound Healing by Modulating Microenvironmental Fibroblasts and Macrophages. Cells. 2022;11(24):4094. doi: 10.3390/cells11244094
  52. Zhang J, Shimozaki K, Hattori S, et al. Metformin lotion promotes scarless skin tissue formation through AMPK activation, TGF-β1 inhibition, and reduced myofibroblast numbers. PLoS One. 2024;19(9):e0311147. doi: 10.1371/journal.pone.0311147
  53. Maghsoodloo D, Zartab H, Alipour M, et al. Topical metformin in wound healing: a comprehensive systematic review of therapeutic outcomes. Arch Dermatol Res. 2025;317(1):760. doi: 10.1007/s00403-025-04277-w
  54. Han X, Tao Y, Deng Y, et al. Metformin accelerates wound healing in type 2 diabetic db/db mice. Mol Med Rep. 2017;16(6):8691-8698. doi: 10.3892/mmr.2017.7707
  55. Pantazopoulos D, Papachristou S, Gouveri E, et al. Metformin: Old Drug, New Therapeutic Potential in the Skin? A Brief Narrative Review. Adv Ther. 2025;42(8):3606-3620. doi: 10.1007/s12325-025-03256-x
  56. Tombulturk FK, Soydas T, Kanigur‐Sultuybek G. Topical metformin accelerates wound healing by promoting collagen synthesis and inhibiting apoptosis in a diabetic wound model. Int Wound J. 2023;21(1):e14345. doi: 10.1111/iwj.14345
  57. Zhao P, Sui B, Liu N, et al. Anti‐aging pharmacology in cutaneous wound healing: effects of metformin, resveratrol, and rapamycin by local application. Aging Cell. 2017;16(5):1083-1093. doi: 10.1111/acel.12635
  58. Ochoa-Gonzalez F, Cervantes-Villagrana AR, Fernandez-Ruiz JC, et al. Metformin Induces Cell Cycle Arrest, Reduced Proliferation, Wound Healing Impairment In Vivo and Is Associated to Clinical Outcomes in Diabetic Foot Ulcer Patients. Veves A, ed. PLoS ONE. 2016;11(3):e0150900. doi: 10.1371/journal.pone.0150900
  59. Salazar JJ, Ennis WJ, Koh TJ. Diabetes medications: Impact on inflammation and wound healing. Journal of Diabetes and its Complications. 2016;30(4):746-752. doi: 10.1016/j.jdiacomp.2015.12.017
  60. Lin YW, Liu PS, Pook KA, Wei LN. Glyburide and retinoic acid synergize to promote wound healing by anti-inflammation and RIP140 degradation. Sci Rep. 2018;8(1):834. doi: 10.1038/s41598-017-18785-x
  61. Hsu CY, Azzam ER, Merza M, et al. Therapeutic potential of repaglinide-embedded chitosan hydrogel in promoting wound healing. Regen Ther. 2025;29:551-562. doi: 10.1016/j.reth.2025.04.021
  62. Stuermer EK, Besser M, Terberger N, Koester V, Bachmann HS, Severing AL. Side effects of frequently used oral antidiabetics on wound healing in vitro. Naunyn-Schmiedeberg’s Arch Pharmacol. 2019;392(3):371-380. doi: 10.1007/s00210-018-01597-9
  63. Vatankhah N, Jahangiri Y, Landry GJ, et al. Effect of systemic insulin treatment on diabetic wound healing. Wound Repair Regeneration. 2017;25(2):288-291. doi: 10.1111/wrr.12514
  64. Wang R, Gu S, Kim YH, et al. Diabetic Wound Repair: From Mechanism to Therapeutic Opportunities. MedComm. 2025;6(10):e70406. doi: 10.1002/mco2.70406
  65. Hu S, Gong Y, Zhang H, et al. The effect of topical insulin therapy on diabetic foot ulcers: A systematic review and meta-analysis. J Tissue Viability. 2025;34(3):100932. doi: 10.1016/j.jtv.2025.100932
  66. Khattab MA, Nabeh OA, Adel S, et al. Topical insulin improves postoperative wound healing in controlled diabetic patients through regulating the expression of E-Cadherin and Ki67: an open-label randomized controlled-trial. Futur J Pharm Sci. 2025;11(1):80. doi: 10.1186/s43094-025-00830-6
  67. Wang J, Xu J. Effects of Topical Insulin on Wound Healing: A Review of Animal and Human Evidences. Diabetes Metab Syndr Obes. 2020;13:719-727. doi: 10.2147/DMSO.S237294
  68. Tani S., Takahashi A., Nagao K., Hirayama A. Effect of dipeptidyl peptidase-4 inhibitor, vildagliptin on plasminogen activator inhibitor-1 in patients with diabetes mellitus. Am J Cardiol. 2015;115(4):454-460. doi: 10.1016/j.amjcard.2014.11.044
  69. Gao W, Chen D, He H, Jiang N, Chen L, Ran X. Sitagliptin, a DPP-4 Inhibitor, Effectively Promotes the Healing of Diabetic Foot Ulcer: A Randomized Controlled Trial. J Diabetes. 2025;17(9):e70156. doi: 10.1111/1753-0407.70156
  70. Mamoun LS, Rosenbloom AJ, Gasbeck T, et al. From Glucose to Gauze: A Systematic Review on the Various Wound Healing Properties of DPP‐4 Inhibitors Beyond Glycaemic Control. Wound Repair Regeneration. 2025;33(5):e70090. doi: 10.1111/wrr.70090
  71. Torrecillas-Baena B, Pulido-Escribano V, Quesada-Gómez JM, et al. Antidiabetic sitagliptin influences tissue regeneration by affecting progenitor cells. Biomedicine & Pharmacotherapy. 2025;189:118279. doi: 10.1016/j.biopha.2025.118279
  72. Katsuhiro M, Hui Teoh S, Yamashiro H, et al. Effects on Glycemic Control in Impaired Wound Healing in Spontaneously Diabetic Torii (SDT) Fatty Rats. Med Arch. 2018;72(1):4-8. doi: 10.5455/medarh.2018.72.4-8
  73. Rykova EY, Klimontov VV, Shmakova E, et al. Anti-Inflammatory Effects of SGLT2 Inhibitors: Focus on Macrophages. Int J Mol Sci. 2025;26(4):1670. doi: 10.3390/ijms26041670
  74. Ullah A, Shen B. Immunomodulatory effects of anti-diabetic therapies: Cytokine and chemokine modulation by metformin, sodium-glucose cotransporter 2 inhibitors, and glucagon-like peptide-1 receptor agonists (2013–2025). European Journal of Medicinal Chemistry. 2025;299:118065. doi: 10.1016/j.ejmech.2025.118065
  75. Lin YH, Lin CH, Lin YC, et al. Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Hospitalization for Heart Failure and Amputation Rate Compared With Incretin-Based Therapy in Patients With Diabetic Foot Disease: A Nationwide Population-Based Study. Endocrine Practice. 2024;30(5):424-430. doi: 10.1016/j.eprac.2024.01.016
  76. Roan JN, Cheng HN, Young CC, et al. Exendin-4, a glucagon-like peptide-1 analogue, accelerates diabetic wound healing. J Surg Res. 2017;208:93-103. doi: 10.1016/j.jss.2016.09.024
  77. Huang H, Wang L, Qian F, et al. Liraglutide via Activation of AMP-Activated Protein Kinase-Hypoxia Inducible Factor-1α-Heme Oxygenase-1 Signaling Promotes Wound Healing by Preventing Endothelial Dysfunction in Diabetic Mice. Front Physiol. 2021;12:660263. doi: 10.3389/fphys.2021.660263
  78. Nagae K, Uchi H, Morino-Koga S, et al. Glucagon-like peptide-1 analogue liraglutide facilitates wound healing by activating PI3K/Akt pathway in keratinocytes. Diabetes Res Clin Pract. 2018;146:155-161. doi: 10.1016/j.diabres.2018.10.013
  79. Turhan B, Sağlam S, Yücel MO, et al. The effects of liraglutide and metformin treatment on fracture healing in partially insulinopenic diabetic rats. Front Endocrinol. 2025;16:1703958. doi: 10.3389/fendo.2025.1703958
  80. Salingaros S, Zhang A, Rohde CH, Spector JA. Active GLP-1 RA Use Is Associated With Lower Rates of Surgical Complications Across Diabetic BMI Cohorts: A Retrospective Analysis of 72,578 Surgical Encounters. Ann Plast Surg. Published online February 13, 2026. doi: 10.1097/SAP.0000000000004657
  81. Hamedi-Shahraki S, Klisic A, Amirkhizi F, Mercantepe F. Association of the triglyceride-glucose index with inflammatory markers and dysregulation of adipokines in patients with metabolic syndrome. BMC Endocr Disord. Published online January 16, 2026. doi: 10.1186/s12902-025-02142-5
  82. Wong CK, Drucker DJ. Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits. Journal of Clinical Investigation. 2025;135(21):e194751. doi: 10.1172/JCI194751
  83. Sugiyama S, Yoshida A, Kurinami N, et al. Once-Weekly Semaglutide Is Associated With Improvement in Vascular Endothelial Function in Patients With Type 2 Diabetes Mellitus: A Retrospective Observational Study. Cureus. 2025;17(12):e99998. doi: 10.7759/cureus.99998
  84. Anastasiou IA, Tentolouris A, Sarantis P, et al. Semaglutide Enhances Cellular Regeneration in Skin and Retinal Cells In Vitro. Pharmaceutics. 2025;17(9):1115. doi: 10.3390/pharmaceutics17091115
  85. Lewis JE, Omenge DK, Patterson AR, et al. The impact of semaglutide on wound healing in diabetes related foot ulcer patients: A TriNetX database study. Diabetes & Vascular Disease Research. 2025;22(2):14791641251322909. doi: 10.1177/14791641251322909
  86. Pastel E, McCulloch LJ, Ward R, et al. GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction. Clin Sci (Lond). 2017;131(5):343-353. doi: 10.1042/CS20160803
  87. Xia Y, Jin J, Sun Y, et al. Tirzepatide’s role in targeting adipose tissue macrophages to reduce obesity-related inflammation and improve insulin resistance. International Immunopharmacology. 2024;143:113499. doi: 10.1016/j.intimp.2024.113499
  88. Hegab II, El-Horany HE sayed, Abd-Ellatif RN, et al. Adropin/Tirzepatide Combination Mitigates Cardiac Metabolic Aberrations in a Rat Model of Polycystic Ovarian Syndrome, Implicating the Role of the AKT/GSK3β/NF-κB/NLRP3 Pathway. IJMS. 2024;26(1):1. doi: 10.3390/ijms26010001
  89. Wilson JM, Lin Y, Luo MJ, et al. The dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis. Diabetes Obesity Metabolism. 2022;24(1):148-153. doi: 10.1111/dom.14553
  90. Masson W, Lobo M, Nogueira JP, et al. Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis. Rev Endocr Metab Disord. Published online October 1, 2025. doi: 10.1007/s11154-025-09991-4
  91. Hu W, Gong W, Yang F, et al. Dual GIP and GLP-1 receptor agonist tirzepatide alleviates hepatic steatosis and modulates gut microbiota and bile acid metabolism in diabetic mice. International Immunopharmacology. 2025;147:113937. doi: 10.1016/j.intimp.2024.113937

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 77760 от 10.02.2020.